Metabolic Host–Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD)

Alexander S Dowdell,Sean P Colgan,Alexander S. Dowdell,Sean P. Colgan

DOI: https://doi.org/10.3390/ph14080708

IF: 4.6

2021-07-22

Pharmaceuticals

Abstract:Inflammatory bowel disease (IBD) is a family of conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. IBD afflicts over 3 million adults in the United States and shows increasing prevalence in the Westernized world. Current IBD treatments center on modulation of the damaging inflammatory response and carry risks such as immunosuppression, while the development of more effective treatments is hampered by our poor understanding of the molecular mechanisms of IBD pathogenesis. Previous genome-wide association studies (GWAS) have demonstrated that gene variants linked to the cellular response to microorganisms are most strongly associated with an increased risk of IBD. These studies are supported by mechanistic work demonstrating that IBD-associated polymorphisms compromise the intestine’s anti-microbial defense. In this review, we summarize the current knowledge regarding IBD as a disease of defects in host–microbe interactions and discuss potential avenues for targeting this mechanism for future therapeutic development.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is related to the pathogenesis of inflammatory bowel disease (IBD) and its relationship with host - microbe interactions. Specifically, the paper explores the following aspects:

1. **Genetic basis of IBD**: The paper discusses that the gut microbiota composition in IBD patients is different from that in healthy individuals, especially emphasizing how IBD - related gene variants affect the host's response to microbes. For example, how variants in the NOD2 and ATG16L1 genes affect the secretion of antimicrobial peptides, the autophagy process, and the control of invading bacteria.

2. **Role of metabolites in IBD**: The paper also explores the important roles of microbial metabolites (such as short - chain fatty acids SCFAs and indole derivatives) in maintaining gut barrier function and regulating immune responses. The deficiency or imbalance of these metabolites may promote the development of IBD.

3. **Role of the microbiome in gut barrier and inflammation**: The paper analyzes how the gut microbiome affects gut barrier function and inflammatory responses through multiple mechanisms, including through the actions of SCFAs and other metabolites. The paper points out that changes in the gut microbiome (such as decreased α - diversity, increased facultative anaerobes, etc.) are closely related to the occurrence and development of IBD.

4. **Future treatment directions**: Based on the above research, the paper proposes potential treatment strategies targeting the host - microbe axis, including restoring gut homeostasis by supplementing specific metabolites and developing drugs targeting G - protein - coupled receptors (GPCRs) activated by SCFAs.

Overall, this paper aims to deeply understand the molecular mechanisms of IBD, especially the role of host - microbe interactions in it, and provide new ideas and directions for future treatments.